The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains
Open accessAbstract
CRISPR-Cas9 genome editing technology holds great promise for discovering therapeutic targets in cancer and other diseases. Current screening strategies target CRISPR-Cas9–induced mutations to the 5′ exons of candidate genes, but this approach often produces in-frame variants that retain functionality, which can obscure even strong genetic dependencies. Here we overcome this limitation by targeting CRISPR-Cas9 mutagenesis to exons encoding functional protein domains. This generates a higher proportion of null mutations and substantially increases the potency of negative selection. We also show that the magnitude of negative selection can be used to infer the functional importance of individual protein domains of interest. A screen of 192 chromatin regulatory domains in murine acute myeloid leukemia cells identifies six known drug targets and 19 additional dependencies. A broader application of this approach may allow comprehensive identification of protein domains that sustain cancer cells and are suitable for drug targeting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Genetic screens in human cells using the CRISPR-Cas9 system
Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014) · Science · doi:10.1126/science.1246981 · Cited by 2,856
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
Self-citationPlat-E: an efficient and stable system for transient packaging of retroviruses
Morita, S., Kojima, T., & Kitamura, T. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301206 · Cited by 1,660
Cited by
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer
Öhlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A. S., Ponz-Sarvise, M., Corbo, V., Oni, T. E., Hearn, S. A., Lee, E. J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162024 · Cited by 2,590
TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
Khan, O., Giles, J. R., McDonald, S., Manne, S., Ngiow, S. F., Patel, K. P., Werner, M. T., Huang, A. C., Alexander, K. A., Wu, J. E., et al. (2019) · Nature · doi:10.1038/s41586-019-1325-x · Cited by 1,646
Genome-scale CRISPR-Cas9 Knockout and Transcriptional Activation Screening
Joung, J., Konermann, S., Gootenberg, J. S., Abudayyeh, O. O., Platt, R. J., Brigham, M. D., Sanjana, N. E., & Zhang, F. (2017) · Nature Protocols · doi:10.1038/nprot.2017.016 · Cited by 1,243
Vu, L. P., Pickering, B. F., Cheng, Y., Zaccara, S., Nguyen, D., Minuesa, G., Chou, T., Chow, A., Saletore, Y., MacKay, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4416 · Cited by 1,237
Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants
Walton, R. T., Christie, K. A., Whittaker, M. N., & Kleinstiver, B. P. (2020) · Science · doi:10.1126/science.aba8853 · Cited by 1,233
Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control
Barbieri, I., Tzelepis, K., Pandolfini, L., Shi, J., Millán-Zambrano, G., Robson, S. C., Aspris, D., Migliori, V., Bannister, A. J., Han, N., et al. (2017) · Nature · doi:10.1038/nature24678 · Cited by 1,086
Self-citationCRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
Komor, A. C., Badran, A. H., & Liu, D. R. (2017) · Cell · doi:10.1016/j.cell.2016.10.044 · Cited by 1,013
Applications of CRISPR technologies in research and beyond
Barrangou, R., & Doudna, J. A. (2016) · Nature Biotechnology · doi:10.1038/nbt.3659 · Cited by 1,005
Tzelepis, K., Koike-Yusa, H., De Braekeleer, E., Li, Y., Metzakopian, E., Dovey, O. M., Mupo, A., Grinkevich, V., Li, M., Mazan, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.079 · Cited by 761
“In fact, recent proof-of-principle studies have demonstrated the potential of this technology to identify cell-essential genes in mammalian cells (Koike-Yusa et al., 2014; Shalem et al., 2014; Shi et al., 2015; Wang et al., 2014).”
BackgroundOff-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
Lin, A., Giuliano, C. J., Palladino, A., John, K. M., Abramowicz, C., Yuan, M. L., Sausville, E. L., Lukow, D. A., Liu, L., Chait, A. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw8412 · Cited by 754
CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells
Liu, S. J., Horlbeck, M. A., Cho, S. W., Birk, H. S., Malatesta, M., He, D., Attenello, F. J., Villalta, J. E., Cho, M. Y., Chen, Y., et al. (2017) · Science · doi:10.1126/science.aah7111 · Cited by 746
Bock, C., Datlinger, P., Chardon, F., Coelho, M. A., Dong, M. B., Lawson, K. A., Lu, T., Maroc, L., Norman, T. M., Song, B., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-021-00093-4 · Cited by 571
CRISPR Interference Efficiently Induces Specific and Reversible Gene Silencing in Human iPSCs
Mandegar, M. A., Huebsch, N., Frolov, E. B., Shin, E., Truong, A., Olvera, M. P., Chan, A. H., Miyaoka, Y., Holmes, K., Spencer, C. I., et al. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.01.022 · Cited by 525
Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance
Liau, B. B., Sievers, C., Donohue, L. K., Gillespie, S. M., Flavahan, W. A., Miller, T. E., Venteicher, A. S., Hebert, C. H., Carey, C. D., Rodig, S. J., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2016.11.003 · Cited by 535
Mayr, C. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a034728 · Cited by 519
Predicting the mutations generated by repair of Cas9-induced double-strand breaks
Allen, F., Crepaldi, L., Alsinet, C., Strong, A. J., Kleshchevnikov, V., De Angeli, P., Páleníková, P., Khodak, A., Kiselev, V., Kosicki, M., et al. (2019) · Nature Biotechnology · doi:10.1038/nbt.4317 · Cited by 496
Development of targeted protein degradation therapeutics
Chamberlain, P. P., & Hamann, L. G. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0362-y · Cited by 489
Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis
Roe, J.-S., Hwang, C.-I., Somerville, T. D. D., Milazzo, J. P., Lee, E. J., Da Silva, B., Maiorino, L., Tiriac, H., Young, C. M., Miyabayashi, K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.007 · Cited by 456
Self-citationAm I ready for CRISPR? A user's guide to genetic screens
Doench, J. G. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.97 · Cited by 452
Integrative analysis of pooled CRISPR genetic screens using MAGeCKFlute
Wang, B., Wang, M., Zhang, W., Xiao, T., Chen, C.-H., Wu, A., Wu, F., Traugh, N., Wang, X., Li, Z., et al. (2019) · Nature Protocols · doi:10.1038/s41596-018-0113-7 · Cited by 446
Cornerstones of CRISPR–Cas in drug discovery and therapy
Fellmann, C., Gowen, B. G., Lin, P.-C., Doudna, J. A., & Corn, J. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.238 · Cited by 443
CRISPR in cancer biology and therapy
Katti, A., Diaz, B. J., Caragine, C. M., Sanjana, N. E., & Dow, L. E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00441-w · Cited by 424
POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer
Huang, Y.-H., Klingbeil, O., He, X.-Y., Wu, X. S., Arun, G., Lu, B., Somerville, T. D. D., Milazzo, J. P., Wilkinson, J. E., Demerdash, O. E., et al. (2018) · Genes & Development · doi:10.1101/gad.314815.118 · Cited by 422
Self-citationCombine and conquer: challenges for targeted therapy combinations in early phase trials
Lopez, J. S., & Banerji, U. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.96 · Cited by 394
The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer
Hodges, C., Kirkland, J. G., & Crabtree, G. R. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026930 · Cited by 414
Systematic comparison of CRISPR/Cas9 and RNAi screens for essential genes
Morgens, D. W., Deans, R. M., Li, A., & Bassik, M. C. (2016) · Nature Biotechnology · doi:10.1038/nbt.3567 · Cited by 401
Dempster, J. M., Boyle, I., Vazquez, F., Root, D. E., Boehm, J. S., Hahn, W. C., Tsherniak, A., & McFarland, J. M. (2021) · Genome Biology · doi:10.1186/s13059-021-02540-7 · Cited by 393
Combinatorial CRISPR–Cas9 screens for de novo mapping of genetic interactions
Shen, J. P., Zhao, D., Sasik, R., Luebeck, J., Birmingham, A., Bojorquez-Gomez, A., Licon, K., Klepper, K., Pekin, D., Beckett, A. N., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4225 · Cited by 359
The cancer epigenome: Concepts, challenges, and therapeutic opportunities
Dawson, M. A. (2017) · Science · doi:10.1126/science.aam7304 · Cited by 377
CRISPRi and CRISPRa Screens in Mammalian Cells for Precision Biology and Medicine
Kampmann, M. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00657 · Cited by 373
Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens
Morgens, D. W., Wainberg, M., Boyle, E. A., Ursu, O., Araya, C. L., Tsui, C. K., Haney, M. S., Hess, G. T., Han, K., Jeng, E. E., et al. (2017) · Nature Communications · doi:10.1038/ncomms15178 · Cited by 360
Munoz, D. M., Cassiani, P. J., Li, L., Billy, E., Korn, J. M., Jones, M. D., Golji, J., Ruddy, D. A., Yu, K., McAllister, G., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0178 · Cited by 359
Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia
Wang, E., Lu, S. X., Pastore, A., Chen, X., Imig, J., Chun-Wei Lee, S., Hockemeyer, K., Ghebrechristos, Y. E., Yoshimi, A., Inoue, D., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.010 · Cited by 338
Self-citationCRISPR/Cas9 for cancer research and therapy
Zhan, T., Rindtorff, N., Betge, J., Ebert, M. P., & Boutros, M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.04.001 · Cited by 328
Transcription control by the ENL YEATS domain in acute leukaemia
Erb, M. A., Scott, T. G., Li, B. E., Xie, H., Paulk, J., Seo, H.-S., Souza, A., Roberts, J. M., Dastjerdi, S., Buckley, D. L., et al. (2017) · Nature · doi:10.1038/nature21688 · Cited by 318
Chen, H., Gao, S., Liu, W., Wong, C.-C., Wu, J., Wu, J., Liu, D., Gou, H., Kang, W., Zhai, J., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.11.013 · Cited by 311
Integrated cross-study datasets of genetic dependencies in cancer
Pacini, C., Dempster, J. M., Boyle, I., Gonçalves, E., Najgebauer, H., Karakoc, E., van der Meer, D., Barthorpe, A., Lightfoot, H., Jaaks, P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21898-7 · Cited by 307
Marked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288
Targeting Transcription Factors in Cancer
Bhagwat, A. S., & Vakoc, C. R. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.07.001 · Cited by 276
Self-citationCRISPR-Cas9 for cancer therapy: Opportunities and challenges
Chen, M., Mao, A., Xu, M., Weng, Q., Mao, J., & Ji, J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.017 · Cited by 272
Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia
Kühn, M. W. M., Song, E., Feng, Z., Sinha, A., Chen, C.-W., Deshpande, A. J., Cusan, M., Farnoud, N., Mupo, A., Grove, C., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0237 · Cited by 264
Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets
Dempster, J. M., Pacini, C., Pantel, S., Behan, F. M., Green, T., Krill-Burger, J., Beaver, C. M., Younger, S. T., Zhivich, V., Najgebauer, H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13805-y · Cited by 253
TP63-mediated enhancer reprogramming drives the squamous subtype of pancreatic ductal adenocarcinoma
Somerville, T. D. D., Xu, Y., Miyabayashi, K., Tiriac, H., Cleary, C. R., Maia-Silva, D., Milazzo, J. P., Tuveson, D. A., & Vakoc, C. R. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.051 · Cited by 225
Self-citationFunctional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands
Gechijian, L. N., Buckley, D. L., Lawlor, M. A., Reyes, J. M., Paulk, J., Ott, C. J., Winter, G. E., Erb, M. A., Scott, T. G., Xu, M., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0010-y · Cited by 222
Survival of pancreatic cancer cells lacking KRAS function
Muzumdar, M. D., Chen, P.-Y., Dorans, K. J., Chung, K. M., Bhutkar, A., Hong, E., Noll, E. M., Sprick, M. R., Trumpp, A., & Jacks, T. (2017) · Nature Communications · doi:10.1038/s41467-017-00942-5 · Cited by 177
Brunetti, L., Gundry, M. C., & Goodell, M. A. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030320 · Cited by 186
Evaluating and enhancing target specificity of gene-editing nucleases and deaminases
Kim, D., Luk, K., Wolfe, S. A., & Kim, J.-S. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111730 · Cited by 171
Multilayered VBC score predicts sgRNAs that efficiently generate loss-of-function alleles
Michlits, G., Jude, J., Hinterndorfer, M., de Almeida, M., Vainorius, G., Hubmann, M., Neumann, T., Schleiffer, A., Burkard, T. R., Fellner, M., et al. (2020) · Nature Methods · doi:10.1038/s41592-020-0850-8 · Cited by 154
HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis
Sun, Y., Zhou, B., Mao, F., Xu, J., Miao, H., Zou, Z., Phuc Khoa, L. T., Jang, Y., Cai, S., Witkin, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.018 · Cited by 152
Generating Single Cell–Derived Knockout Clones in Mammalian Cells with CRISPR/Cas9
Giuliano, C. J., Lin, A., Girish, V., & Sheltzer, J. M. (2019) · Current Protocols in Molecular Biology · doi:10.1002/cpmb.100 · Cited by 130
Bak, R. O., Dever, D. P., Reinisch, A., Cruz Hernandez, D., Majeti, R., & Porteus, M. H. (2017) · eLife · doi:10.7554/elife.27873 · Cited by 122
“This error-prone system creates a heterogeneous mixture of cells with various genotypes of SNPs and small insertions or deletions (INDELs); moreover, not all of the genetic changes from INDELs cause functional gene disruption as they may preserve the open reading frame and may not change amino acids essential for prot…”
BackgroundeIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma
Chan, K., Robert, F., Oertlin, C., Kapeller-Libermann, D., Avizonis, D., Gutierrez, J., Handly-Santana, A., Doubrovin, M., Park, J., Schoepfer, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13086-5 · Cited by 106
Self-citationLiscovitch-Brauer, N., Montalbano, A., Deng, J., Méndez-Mancilla, A., Wessels, H.-H., Moss, N. G., Kung, C.-Y., Sookdeo, A., Guo, X., Geller, E., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00902-x · Cited by 107
Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth
Kim, W., Lee, S., Kim, H. S., Song, M., Cha, Y. H., Kim, Y.-H., Shin, J., Lee, E.-S., Joo, Y., Song, J. J., et al. (2018) · Genome Research · doi:10.1101/gr.223891.117 · Cited by 97
Surface antigen-guided CRISPR screens identify regulators of myeloid leukemia differentiation
Wang, E., Zhou, H., Nadorp, B., Cayanan, G., Chen, X., Yeaton, A. H., Nomikou, S., Witkowski, M. T., Narang, S., Kloetgen, A., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2020.12.005 · Cited by 66
Self-citationDe novo identification of essential protein domains from CRISPR-Cas9 tiling-sgRNA knockout screens
He, W., Zhang, L., Villarreal, O. D., Fu, R., Bedford, E., Dou, J., Patel, A. Y., Bedford, M. T., Shi, X., Chen, T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12489-8 · Cited by 69
Assigning functionality to cysteines by base editing of cancer dependency genes
Li, H., Ma, T., Remsberg, J. R., Won, S. J., DeMeester, K. E., Njomen, E., Ogasawara, D., Zhao, K. T., Huang, T. P., Lu, B., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01428-w · Cited by 62
Customizing the genome as therapy for the β-hemoglobinopathies.
Canver, M. C., & Orkin, S. H. (2016) · Blood · doi:10.1182/blood-2016-01-678128 · Cited by 61
Jia, Y., Li, L., Lin, Y.-H., Gopal, P., Shen, S., Zhou, K., Yu, X., Sharma, T., Zhang, Y., Siegwart, D. J., et al. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.01.001 · Cited by 59
Profiling the Landscape of Drug Resistance Mutations in Neosubstrates to Molecular Glue Degraders
Gosavi, P. M., Ngan, K. C., Yeo, M. J. R., Su, C., Li, J., Lue, N. Z., Hoenig, S. M., & Liau, B. B. (2022) · ACS Central Science · doi:10.1021/acscentsci.1c01603 · Cited by 56
Kotagama, O. W., Jayasinghe, C. D., & Abeysinghe, T. (2019) · BioMed Research International · doi:10.1155/2019/1369682 · Cited by 48
High-resolution characterization of gene function using single-cell CRISPR tiling screen
Yang, L., Chan, A. K. N., Miyashita, K., Delaney, C. D., Wang, X., Li, H., Pokharel, S. P., Li, S., Li, M., Xu, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24324-0 · Cited by 45
Inducible knock-out of BCL6 in lymphoma cells results in tumor stasis
Schlager, S., Salomon, C., Olt, S., Albrecht, C., Ebert, A., Bergner, O., Wachter, J., Trapani, F., Gerlach, D., Voss, T., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27506 · Cited by 36
“CRISPR/Cas9 genome editing frequently generates in-frame mutations instead of insertions or deletions, and thus a certain percentage of cells with silent or nonfunctional mutations are expected [36].”
BackgroundPentose conversions support the tumorigenesis of pancreatic cancer distant metastases
Bechard, M. E., Word, A. E., Tran, A. V., Liu, X., Locasale, J. W., & McDonald, O. G. (2018) · Oncogene · doi:10.1038/s41388-018-0346-5 · Cited by 35
Ghiboub, M., Elfiky, A. M. I., de Winther, M. P. J., Harker, N. R., Tough, D. F., & de Jonge, W. J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050336 · Cited by 28
Usher, J., & Haynes, K. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008259 · Cited by 27
“This has recently been demonstrated in the context of cancer, where Cas9 mediated genome editing was used to target chromatin regulatory domains in a murine acute myeloma cell line, identifying six known drug targets, and a further 19 genes that are essential in this cancer cell line [9].”
BackgroundRapid interrogation of cancer cell of origin through CRISPR editing
Feng, W., Cao, Z., Lim, P. X., Zhao, H., Luo, H., Mao, N., Lee, Y. S., Rivera, A. A., Choi, D., Wu, C., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110344118 · Cited by 25
CRISP-view: a database of functional genetic screens spanning multiple phenotypes
Cui, Y., Cheng, X., Chen, Q., Song, B., Chiu, A., Gao, Y., Dawson, T., Chao, L., Zhang, W., Li, D., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa809 · Cited by 24
Activity-based CRISPR scanning uncovers allostery in DNA methylation maintenance machinery
(2023) · doi:10.7554/elife.80640 · Cited by 16
CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges
Chen, M., Xu, J., Zhou, Y., Zhang, S., & Zhu, D. (2020) · Briefings in Functional Genomics · doi:10.1093/bfgp/elz027 · Cited by 12
Yuan, W.-C., Earl, A. S., Ma, S., Alcedo, K., Russell, J. O., Duarte, F. M., Chu, Y.-T., Chang, P.-C., Chen, H.-Y., Chi, H.-H., et al. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2025.04.010 · Cited by 7
(2016) · doi:10.13918/j.issn.2095-8137.2016.4.191
Metadata
- Authors
- Shi, J., Wang, E., Milazzo, J. P., Wang, Z., Kinney, J. B., & Vakoc, C. R.
- Venue
- Nature Biotechnology
- Published
- 2015-05-11
- Volume
- 33
- Issue
- 6
- Pages
- 661-667
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W1635615463
- Cited by
- 761
- References
- 26
- FWCI
- 31.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.